Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.
Animals
Antineoplastic Agents
/ chemical synthesis
Breast Neoplasms
/ drug therapy
Dogs
Drug Screening Assays, Antitumor
Estrogen Receptor Antagonists
/ chemical synthesis
Estrogen Receptor alpha
/ metabolism
Heterocyclic Compounds, 3-Ring
/ chemical synthesis
Humans
Indazoles
/ chemical synthesis
MCF-7 Cells
Male
Mice, SCID
Microsomes, Liver
/ metabolism
Molecular Structure
Rats
Structure-Activity Relationship
Xenograft Model Antitumor Assays
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
14 02 2019
14 02 2019
Historique:
pubmed:
15
1
2019
medline:
4
3
2020
entrez:
15
1
2019
Statut:
ppublish
Résumé
Herein, we report the identification and synthesis of a series of tricyclic indazoles as a novel class of selective estrogen receptor degrader antagonists. Replacement of a phenol, present in our previously reported tetrahydroisoquinoline scaffold, with an indazole group led to the removal of a reactive metabolite signal in an in vitro glutathione trapping assay. Further optimization, guided by X-ray crystal structures and NMR conformational work, varied the alkyl side chain and pendant aryl group and resulted in compounds with low turnover in human hepatocytes and enhanced chemical stability. Compound 9 was profiled as a representative of the series in terms of pharmacology and demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.
Identifiants
pubmed: 30640465
doi: 10.1021/acs.jmedchem.8b01837
doi:
Substances chimiques
Antineoplastic Agents
0
Estrogen Receptor Antagonists
0
Estrogen Receptor alpha
0
Heterocyclic Compounds, 3-Ring
0
Indazoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM